Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04606030 · ClinicalTrials.gov registry record · NA

LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge)

A NA study of Lymphedema and Edema, sponsored by Fibralign Corporation.

Recruiting
Registry status
NA
Development phase
60
Enrollment target
2
Study locations

NCT04606030 is a NA study of Lymphedema and Edema that is actively recruiting participants, run by Fibralign Corporation. The registered enrollment target is 60 participants, below the 9,298-participant average among 34 other Lymphedema trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04606030, a NA study of Lymphedema and Edema, is actively recruiting participants, sponsored by Fibralign Corporation.

RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
2
Study locations

Study Summary

To investigate whether the addition of Fibralign's BioBridge® Collagen Matrix (BioBridge) devices to the standard surgery for vascularized lymph node transfer will improve the outcome of surgical treatment in lymphedema of the upper arm.

Conditions Studied

Interventions

  • DEVICE BioBridge® Collagen Matrix
  • PROCEDURE Vascularized Lymph Node Transfer (VLNT)

Study Locations (2)

Illinois

  • The University of Chicago Biological Sciences Division/University of Chicago Medical Center - Chicago

Texas

  • MD Anderson - Houston

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2020-10-26
Est. Completion 2025-12-30
Phase NA

Sponsor

Fibralign Corporation

2 total trials

What the Registry Record Tells You About NCT04606030

The ClinicalTrials.gov registry entry for NCT04606030 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 9,298-participant average among 34 other Lymphedema trials with a reported enrollment target (99% lower). The listed sponsor is Fibralign Corporation, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Lymphedema appearing as the primary indexed condition, and to 2 interventions - of which BioBridge® Collagen Matrix is the first listed.

NCT04606030 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Illinois, Texas.

Frequently Asked Questions

What is clinical trial NCT04606030 about?

NCT04606030 is a clinical study titled "LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge)". To investigate whether the addition of Fibralign's BioBridge® Collagen Matrix (BioBridge) devices to the standard surgery for vascularized lymph node transfer will improve the outcome of surgical treatment in lymphedema of the upper arm.

What is the current status of trial NCT04606030?

This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2020-10-26. Estimated completion is 2025-12-30.

What conditions does trial NCT04606030 study?

This clinical trial studies the following conditions: Lymphedema, Edema.

What interventions are being tested in trial NCT04606030?

The interventions under investigation include: BioBridge® Collagen Matrix (DEVICE), Vascularized Lymph Node Transfer (VLNT) (PROCEDURE).

Who is sponsoring clinical trial NCT04606030?

This trial is sponsored by Fibralign Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04606030 being conducted?

This trial has 2 study locations across Illinois, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lymphedema

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.